{"name":"Revance Therapeutics, Inc.","slug":"revance-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":413000,"revenueGrowth":797.8,"grossMargin":0,"rdSpend":79410000,"netIncome":-323986000,"cash":137329000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"DAXXIFY","genericName":"DAXIBOTULINUMTOXINA-LANM","slug":"daxibotulinumtoxina-lanm","indication":"Other","status":"marketed"},{"name":"DAXI for injection 250 U","genericName":"DAXI for injection 250 U","slug":"daxi-for-injection-250-u","indication":"Glabellar lines (frown lines) in adults","status":"phase_2"},{"name":"DAXI for injection 375 U","genericName":"DAXI for injection 375 U","slug":"daxi-for-injection-375-u","indication":"Other","status":"phase_2"},{"name":"DAXXIFY","genericName":"DAXXIFY","slug":"daxxify","indication":"Other","status":"marketed"},{"name":"DaxibotulinumtoxinA for injection","genericName":"DaxibotulinumtoxinA for injection","slug":"daxibotulinumtoxina-for-injection","indication":"Glabellar lines (frown lines) for aesthetic use","status":"phase_3"}]}],"pipeline":[{"name":"DAXXIFY","genericName":"DAXIBOTULINUMTOXINA-LANM","slug":"daxibotulinumtoxina-lanm","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"DAXI for injection 250 U","genericName":"DAXI for injection 250 U","slug":"daxi-for-injection-250-u","phase":"phase_2","mechanism":"DAXI is a botulinum toxin type A formulation that blocks acetylcholine release at the neuromuscular junction to reduce muscle contractions.","indications":["Glabellar lines (frown lines) in adults","Cervical dystonia"],"catalyst":""},{"name":"DAXI for injection 375 U","genericName":"DAXI for injection 375 U","slug":"daxi-for-injection-375-u","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"DAXXIFY","genericName":"DAXXIFY","slug":"daxxify","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"DaxibotulinumtoxinA for injection","genericName":"DaxibotulinumtoxinA for injection","slug":"daxibotulinumtoxina-for-injection","phase":"phase_3","mechanism":"DaxibotulinumtoxinA is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.","indications":["Glabellar lines (frown lines) for aesthetic use","Cervical dystonia","Blepharospasm","Hemifacial spasm"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-19","type":"regulatory","source":"einnews.com","summary":"Hyaluronic Acid-Based Dermal Fillers Market 2026 growing due to rising demand for aesthetic treatments - einnews.com","headline":"Hyaluronic Acid-Based Dermal Fillers Market 2026 growing due to rising demand for aesthetic treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQTWF3T0tNcThwTjk3UGl2SWwtYlAzTlNKWkVhc19sSHZpc0VieUZnNm1VT3pBMHpZYnJsd0p6ak5CT2FDVmU5VExZdkRTRGdjNjJUMFFvWXU0TWFlS1VxUjJxRnBjam5oTG90bUhrVFlJSUg0TngzMXNEOUhBbmhUOWhB?oc=5","date":"2025-09-10","type":"pipeline","source":"Fortune Business Insights","summary":"Therapeutic Neurotoxin Market Size, Share & Growth Report, 2034 - Fortune Business Insights","headline":"Therapeutic Neurotoxin Market Size, Share & Growth Report, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOSFQ4bUhxaE9reVBrMDZQSlBudlpUQzJObnZiN1J1VmFaMjFDNjc4VVcybFc3ZW9icTVITG1TeVR4M24yQ2puM1hUMGpqaVFTRGxVUllSSFBLNnZuQ2xreWVvOFVLeFFmbS02dlBRcjBWOFk4SmhJdmdCU1RQb3ZnaWtEWXJmb0Zwbjljc2UyeWJVdW1XSGJyOXBHMkFWNlQ4UmdaWVBodw?oc=5","date":"2025-07-22","type":"patent","source":"Fierce Pharma","summary":"AbbVie wins $56M royalty award from Revance in Botox patent infringement case - Fierce Pharma","headline":"AbbVie wins $56M royalty award from Revance in Botox patent infringement case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNMVNRS3ZuZ3dxMUNYN3VVam8tdUljaU9Dc0RZYkoxQXpzNF9kUk1TU3phZFoyVXRkaFJ4a1hvc2NfMFd5aFl0UG9ZTUpIb0hoeXhlVU5xY3UteVhqR1FNb0dTMU1PVkdaVXVqLVlfbC1YbHAxajlJRTBfS0N2SE9ZaE81bGthVkZVdk1WZXZEeW01UGxTdkFORkVHd0hpTGZBRmc?oc=5","date":"2025-06-25","type":"deal","source":"Pharmaceutical Technology","summary":"Revolution Medicines partners Royalty Pharma on $2bn funding - Pharmaceutical Technology","headline":"Revolution Medicines partners Royalty Pharma on $2bn funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1ZY2lrYWVWc2g5b290X3IzYk1HUWpDQWVkT0kxUGE5eVFNMTY5bHRReVc4WnE0TVZ1cHZiU3lFR29lei1kM29iNkk1c056SkExMDlXTmlaWGFWZmQzU0NqUXNHbzJYRkVTRnZLd2RJVmczRWZSbEVJNTk4TQ?oc=5","date":"2025-05-12","type":"earnings","source":"Precedence Research","summary":"Botulinum Toxin Market Revenue to Attain USD 19.68 Bn by 2033 - Precedence Research","headline":"Botulinum Toxin Market Revenue to Attain USD 19.68 Bn by 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOLTAtSHJ4bHQ4VUF0bDBKZURSOG5BMjNsUWcyZXVvdkd2RUYwTERSY2hob3BYYWdKaGI5bWswWEdjRXZ2UDNtODkwZWxXWHdRdF93a19ZUE41bmZqWFMxRDkxel9GaWxwNlU0bTJ1SURRRkJWZk1Vb0xmdFd2LWlqTmFtS3RvaWpETGZ5Y0FKYTlHNFZpdU9TbUE0U3E0RW8ybWJrNUl0eUNId1FFZWI2TmRn?oc=5","date":"2025-04-04","type":"pipeline","source":"The Business Journals","summary":"Bay Area drug veteran heads New Zealand company's oral ketamine spinoff targeting depression - The Business Journals","headline":"Bay Area drug veteran heads New Zealand company's oral ketamine spinoff targeting depression","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOaC1UZm9jS1pRWjZpY0pvVUFLR0tkNXFnTHVnbDE2dzFHSnVZZkgtSUp1aE5QOWZaOXRCd3lJR244RFBZRkNmdmNDSGxmRHVoMkpmZnh0RF9WN1k5QTdrVWJoWUgzNlZVWmZITVJlNzlfaHFTaDhpbDlOcG1Gb01rMjlPNGxtZzBRVTQyY01TMnF6SjlOWko5OV9pZWNwUDFRMW44Xzd4aHMyQjNUYnVieFV3RHNrSXo5TTZKM213?oc=5","date":"2025-02-07","type":"pipeline","source":"Business Wire","summary":"Crown Laboratories Completes Acquisition of Revance Therapeutics - Business Wire","headline":"Crown Laboratories Completes Acquisition of Revance Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQQm8tWERCRFhoWFZlVDJXamFTSk1hZXQ4VnBGOFJCOEVHcWpxWm41OWNJbkpVeXBMd2I4VkxKYXFSY0FReTJqTWZRdUN1YkdudmxWaXExbmp3N2stSDlTZGFNaUpNaHpLRkJuT2QzSktaTEFBUUp3amMwamVxZE56N1ZzUUVIbVVuTU1oVlExWjA1Wm4xSGN6eUpvUHBvWFJRWkQxYzFWOHF3bGxFWGZIYTh3?oc=5","date":"2024-08-14","type":"deal","source":"Contract Pharma","summary":"Crown Laboratories and Revance Therapeutics Enter Merger Agreement - Contract Pharma","headline":"Crown Laboratories and Revance Therapeutics Enter Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPTi13b2EyTzl6MW5IemZ6RTNGZ3VNeW5CQUp4RHVMTnpVZTBjdjBEOXlEYVNlVGl0cUpjTjJnakYxaXVPLTJfOThIVjFxcng4N3M2bk5KLXZlbHc5WGFNc28zYkxpTUcySmRsNkRUOGI5a2hReXpxM2RLTUVqRld6RzBQX1llNWFzWVN6a3RmU2ZmZk02V3VLRU1fcmFEV3NvU3BTVWxiQkswMzU1NXc?oc=5","date":"2024-06-20","type":"pipeline","source":"Seeking Alpha","summary":"Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes (NASDAQ:RVNC) - Seeking Alpha","headline":"Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes (NASDAQ:RVNC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNQm1ZMjVTWVBpbUpLYWZ6Rms1Rl9tMlRHdTVUVTNGZEZRZDFyYzVTT3h3UFJfY2puSnR3Sm1NWGlNVjRqcy1zdngxblVzNmxKYkhxRnYwaVIzMHlGQ09sNVZRVk5LalppZjRLQ0lHNk9xTThfcXRWeGQxMmd1ZjNsZWlrMjAyb2lQVjdjUk1XeVRSM002eUU2dHh2a3l6SVU?oc=5","date":"2023-05-03","type":"pipeline","source":"hcamag.com","summary":"Big pharma in Botox employee battle - hcamag.com","headline":"Big pharma in Botox employee battle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPVERleXhNQzJQaFJnSlVZWmZta3dSZmkyeGhhc01PTXhlckU4cTFTX1B3MXdQR1BLc3lnUE9iaGsySGdRajBxVXA4QzZDb2xpQzViLXczeTJTdXM2UjVWWENyRDRMREpsTGRIYlR2V3NtNGRNX05Xd3NuZXg4WUVoeTlOdHJyNDhqZEJCaVhKSlZXa3MxMU9xYnFoVm9Td3g3WHdwQXdoZUNDazJGMjJFRUNNRDlkdk0xczhMOWk5MEp4d0pVSGpOcmlGNXJXNkNlSjVPVG5JWGF5RVhlSTAxX25LSGRyVDh3cERoNzAtb2RwY3FaNHJzUVRiMUt4WWh6RFR5d2ZRdWxwRUNhRU00WUI2cFJkUmZXWHo0?oc=5","date":"2020-12-22","type":"pipeline","source":"PR Newswire","summary":"Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of DaxibotulinumtoxinA for Injection - PR Newswire","headline":"Ajinomoto Bio-Pharma Services and Revance Therapeutics Announce Manufacturing Agreement for Supply of Daxibotulinumtoxin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNTGg2Ym5GREtBSVhZVlR0WEhnYVB3djZPYzJ3U0RWbnhTM3RyZ0VFaW9uWnFwS1FrNnJQLXhTcXBwRUMtUHlBekZHSElYbWY3dUdWeVh4bEY4V2xyOG4zRl82T3pEeTNmbHZnQmlRX0YzdjFOd2N0N3lrb1ZTUXRQSFRqYlZWdXRMZTV2QnRzS19CQ2w5VXJ3T2tJU1djblpTbWc?oc=5","date":"2018-03-01","type":"deal","source":"BioPharma Dive","summary":"Mylan partners with Revance to develop a Botox biosimilar - BioPharma Dive","headline":"Mylan partners with Revance to develop a Botox biosimilar","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":2,"phase_2":2,"phase_3":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":413000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":413000,"period":"2019-12-31"},{"value":46000,"period":"2019-09-30"},{"value":0,"period":"2019-06-30"},{"value":278000,"period":"2019-03-31"},{"value":3729000,"period":"2018-12-31"},{"value":2362000,"period":"2018-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":79410000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-323986000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":137329000,"cashHistory":[],"totalAssets":478454000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}